CORMEDIX INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted
CORMEDIX INC. (CRMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted of 450.00 thousand shares for the 12-month period ending 2018-12-31, per its 10-K filed 2019-05-29.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted · last filed 2019-05-29
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2018 was 450.00K shares, a 98.48% decline from fiscal 2017.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2017 was 29.61M shares.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2015 was 6.99 shares, a 219.18% increase from fiscal 2014.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2014 was 2.19 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month |
|---|---|
| 2018-12-31 | 450.00K shares 10-K · filed 2019-05-29 |
| 2017-12-31 | 29.61M shares 10-K · filed 2018-03-19 |
| 2015-12-31 | 6.99 shares 10-K · filed 2016-03-15 |
| 2014-12-31 | 2.19 shares 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |